Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2

EU orphan designation number: EU/3/11/866   
Active ingredient: Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2
Indication: Treatment of acute myeloid leukaemia
Sponsor: Fate Therapeutics, LTD
c/o Gregor Frizzell, Covington & Burling LLP, 265 Strand, London WC2R 1BH, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
17/05/2011 Centralised Orphan - Designation EMA/OD/161/10 (2011)3492 of 13/05/2011